The objective of the proposed work is to develop and characterize vaccines based on virus-like particles (VLPs) presenting multiple copies of the Zika virus (ZIKV) envelope (E) protein. The ongoing ZIKV epidemic constitutes a serious public health problem with the linkage to an increase in reported cases of congenital microcephaly causing particular concern. An effective vaccine against ZIKV is therefore a critical unmet need. Moreover, given the necessity of administering such a vaccine to pregnant women, it would be useful to develop alternatives to vaccines based on live attenuated viruses as well as to explore vaccines that may confer protection without the use of adjuvants. In previous work, we have designed nanoscale scaffolds presenting other viral glycoprotein antigens that elicited protective immune responses in vivo. We also have expertise in testing the efficacy of vaccines and monoclonal antibodies in vivo.
The first aim of the proposed work is to design and characterize nanoscale constructs based on VLPs presenting monomers of the ZIKV E protein.
The second aim i s to stabilize dimers of the ZIKV E protein and to characterize and optimize the immunogenicity of VLPs presenting the dimers. We anticipate that this approach will yield nanoscale constructs that present ZIKV antigens in a controlled orientation and elicit high titers of neutralizing antibodies. The proposed studies will not only help us identify promising candidates that can be moved forward into more extensive pre-clinical studies, but will also yield reagents that will be useful for characterizing the human antibody response to ZIKV infection.

Public Health Relevance

The objective of the proposed work is to develop Zika virus vaccines based on nanoscale scaffolds presenting multiple copies of the envelope protein. The research is relevant to public health because it could lead to the development of new and effective Zika virus vaccines. The proposed approaches may also enable the design of more effective vaccines against other flaviviruses.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI129477-02
Application #
9557522
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Challberg, Mark D
Project Start
2017-09-10
Project End
2019-08-31
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Georgia Institute of Technology
Department
Engineering (All Types)
Type
Biomed Engr/Col Engr/Engr Sta
DUNS #
097394084
City
Atlanta
State
GA
Country
United States
Zip Code
30318
Frey, Steven; Castro, Ana; Arsiwala, Ammar et al. (2018) Bionanotechnology for vaccine design. Curr Opin Biotechnol 52:80-88
Bailey, Mark J; Duehr, James; Dulin, Harrison et al. (2018) Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model. Nat Commun 9:4560